References
- Damas AM, Saraiva MJ. TTR Amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies. J Struct Biol 2000;130:290–299.
- Blaney JM, Jorgensen EC, Conolly ML, Ferrin TE, Langridge R, Oatley SJ, Burridge JM, Blake CC, Computer Graphics in Drug Design: Molecular modeling of thyroid hormone – Prealbumin Interactions. J Med Chem 1982;25:785–790.
- Munro SL, Lim CF, Hall JG, Barlow JW, Craik DJ, Topliss DJ, Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine – binding globulin. J Clin Endocrinol Metab 1989;68:1141–1147.
- Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 2004;47:355–374.
- Mairal T, Nieto J, Pinto M, Almeida MR, Gales L, Ballesteors A, Saraiva MJ, Damas AM, Planas A, Arsequell G, Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE 2009;4(1),13.
- Montreal: MOE, Chemical Computing Group Inc. Availble from: http://www.chemcomp.com.
- Wolber G, Langer TJ. Chem Inf Model 2005;45:160–169. Available from: http://www.inteligand.com.
- Muzio T, Cody V, Wojtczak A. Comparison of binding interactions of dibromoflavonoids with transthyretin. Acta Biochim Polon 2001;48:885–892.
- Masciocchi J, Frau G, Fanton M, Sturlese M, Floris M, Pireddu L, Palla P, Cedrati F, Rodriguez-Tome P, Moro S. MMsINC: a large-scale chemoinformatics database. Nucleic Acids Res 2009;37:284.
- Lueprasitsakul W, Alex S, Fang SL, Pino S, Irmscher K, Braverman LE. Flavonoid administration immediately displaces thyroxine (T4) from serum transthyretin, increases serum free (T4) and decreases serum thyrotropin in the rat. Endocrinology 1990;126:2890–2895.